Aurora Cannabis Rejects Curaleaf’s Hostile Takeover Bid as Undervalued
Event summary
- Curaleaf Holdings launched an unsolicited takeover bid for Aurora Cannabis at US$4.00 per share, capped at US$5.00.
- Aurora’s shares have traded higher than the offer price as recently as December 18, 2025.
- Aurora’s board has formed a special committee to evaluate the offer and will recommend a course of action within 15 days.
- The offer remains open for at least 105 days, with Aurora shareholders advised to take no action until the board’s recommendation.
- Aurora has been in dialogue with Curaleaf since June 2026, with the latest contact on August 12, 2026.
The big picture
Aurora Cannabis is pushing back against Curaleaf’s hostile takeover bid, framing it as an attempt to undervalue its strategic assets. The move highlights the ongoing consolidation in the cannabis industry, where larger players seek to acquire specialized facilities and medical platforms at a discount. Aurora’s defense strategy will test whether its long-term growth narrative can outweigh short-term financial pressure from shareholders.
What we're watching
- Valuation Dispute
- Whether Curaleaf’s offer accurately reflects Aurora’s strategic assets, particularly its EU-GMP facilities and global medical cannabis platform.
- Shareholder Response
- How Aurora’s shareholders will react to the board’s recommendation, given the company’s emphasis on long-term strategy.
- Regulatory Scrutiny
- The potential for regulatory review of the proposed transaction, given the scale of the deal and the competitive landscape.